Overexpression of HIF-1α confers doxorubicin resistance in AML cells and synergizes with leukemia-derived macrophage migration inhibitory factor (MIF) to enhance cellular proliferation and survival. This evidence concerns the gene MIF and acute myeloid leukemia.